Obagi Medical Shareholder Alert: Briscoe Law Firm And Powers Taylor, LLP Investigate Sale To Valeant Pharmaceuticals

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating the sale of Obagi Medical Products, Inc. (“Obagi”) (NasdaqGS: OMPI) to Valeant Pharmaceuticals International, Inc. for shareholders. Under the terms of the proposed transaction valued at approximately $360 million, Obagi shareholders will only receive $19.75 in cash for each share of stock owned.

If you are an affected investor, and you want to learn more about the lawsuit or join the action, contact Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 239-4568, or via email at WBriscoe@TheBriscoeLawFirm.com, or Zach Groover at Powers Taylor, LLP, toll free (877) 728-9607, via e-mail at zach@powerstaylor.com. There is no cost or fee to you.

The Obagi sale investigation centers on whether Obagi’s shareholders are receiving adequate compensation for their shares in the buyout, whether the transaction undervalues Obagi’s stock, and whether Obagi’s board attempted to obtain the highest share price for all shareholders prior to agreeing to the deal. Shareholder rights attorney Willie Briscoe commented that “based upon the proposed sale price, recent financial performance, and other factors, we believe this transaction may undervalue Obagi’s stock. Our proposed lawsuit will seek to ensure that shareholders are receiving the highest share price for their shares.”

The Briscoe Law Firm, PLLC is a full service business litigation and shareholder rights advocacy firm with more than 20 years of experience in complex litigation and transactional matters.

Powers Taylor, LLP is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions.

Copyright Business Wire 2010

If you liked this article you might like

The Five Dumbest Things on Wall Street: April 12

The Five Dumbest Things on Wall Street: April 12

Merz Withdrawal Frees Obagi-Valeant Merger

Merz Withdrawal Frees Obagi-Valeant Merger

Valeant Buys Obagi Medical for $360 Million

Valeant Buys Obagi Medical for $360 Million

Obagi Medical Products Inc. Stock Downgraded (OMPI)

Obagi Medical Products Inc. Stock Downgraded (OMPI)

5 Hated Stocks Set to Soar on Earnings

5 Hated Stocks Set to Soar on Earnings